Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification (Q38097027)

28 August 2017

title

Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification (English)

1 reference

28 August 2017

1 reference

Keith M Kerr

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

6 April 2013

1 reference

Journal of Clinical Pathology

28 August 2017

published in

1 reference

28 August 2017

volume

66

1 reference

28 August 2017

issue

10

1 reference

28 August 2017

page(s)

832-838

1 reference

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

TTF-1 expression in pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Immunoexpression of P16INK4a, Rb and TP53 proteins in bronchiolar columnar cell dysplasia (BCCD) in lungs resected due to primary non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Differential diagnosis of ground-glass opacity nodules: CT number analysis by three-dimensional computerized quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Small adenocarcinoma of the lung. Histologic characteristics and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Bronchogenic carcinoma and coexistent bronchioloalveolar cell adenomas. Assessment of radiologic detection and follow-up in 28 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Diagnosis of lung cancer by fibreoptic bronchoscopy: problems in the histological classification of non-small cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS-FNA cytological samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Genetically informed lung cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201519

10.1136/JCLINPATH-2013-201519

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference